Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1

作者：

Lipschitz, Noga ^{[1
]}

Earl, Brian R. ^{[1
,2
]}

Cripe, Timothy P. ^{[3
,4
]}

Samy, Ravi N. ^{[1
,5
,6
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA

[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA

[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA

[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA

[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA

[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

来源：

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期

关键词：

cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;

D O I：

10.1097/MOO.0000000000000651

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.

引用

页码：281 / 285

页数：5

共 50 条

[31] The combination therapy of oncolytic virotherapy
Wang, Yue
Zhu, Mengying
Chi, Huanyu
Liu, Yang
Yu, Guilin
FRONTIERS IN PHARMACOLOGY, 2024, 15
[32] Oncolytic virotherapy: the questions and the promise
Aurelian, Laure
ONCOLYTIC VIROTHERAPY, 2013, 2 : 19 - 29
[33] Oncolytic Virotherapy and the Tumor Microenvironment
Berkey, Sara E.
Thorne, Steve H.
Bartlett, David L.
TUMOR IMMUNE MICROENVIRONMENT IN CANCER PROGRESSION AND CANCER THERAPY, 2017, 1036 : 157 - 172
[34] Cancer virotherapy with oncolytic adenoviruses
Alemany, R.
HUMAN GENE THERAPY, 2016, 27 (11) : A20 - A20
[35] Oncolytic Virotherapy for Hematological Malignancies
Bais, Swarna
Bartee, Eric
Rahman, Masmudur M.
McFadden, Grant
Cogle, Christopher R.
ADVANCES IN VIROLOGY, 2012, 2012
[36] Oncolytic virotherapy for ovarian cancer
Li, Shoudong
Tong, Jessica
Rahman, Masmudur M.
Shepherd, Trevor G.
McFadden, Grant
ONCOLYTIC VIROTHERAPY, 2012, 1 : 1 - 21
[37] Oncolytic Virotherapy with Myxoma Virus
Rahman, Masmudur M.
McFadden, Grant
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
[38] Oncolytic virotherapy for pancreatic cancer
Wennier, Sonia
Li, Shoudong
McFadden, Grant
EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e18
[39] Redemption for the Field of Oncolytic Virotherapy
Kirn, David H.
MOLECULAR THERAPY, 2011, 19 (04) : 627 - 628
[40] Oncolytic virotherapy safe and effective
Richards, Dan
FUTURE VIROLOGY, 2006, 1 (05) : 539 - 539

← 1 2 3 4 5 →